InvestorsHub Logo
Followers 3
Posts 210
Boards Moderated 0
Alias Born 09/13/2013

Re: None

Wednesday, 01/22/2014 8:42:01 AM

Wednesday, January 22, 2014 8:42:01 AM

Post# of 21475
MCIG NEWS NEWS NEWS

mCig, Inc. - Forms Medical Advisory Board In Preparation For Next Line of Products



BELLEVUE, WA--(January 22, 2014) - mCig, Inc. (Stock Market Symbol: MCIG) is pleased to announce the formation of a Medical Advisory Board to help oversee the company’s strategy and assist in the preparation to enter new markets. The first addition to the board is Dr. Khary Bryan, the official representative of Cannatest in the New England States.



Dr. Khary Bryan Biography:

Dr. Khary Bryan is a 2001 graduate of the Philadelphia College of Pharmacy. During the six years of Doctor of Pharmacy training, his personal goal was to learn different methods of disease prevention in addition to the pharmaceutical management of disease. It was during this time he discovered the role of nutraceuticals and functional foods in the prevention and treatment of disease, although his parents exposed him to herbal medicine and a disease prevention lifestyle from an early age. In 2010 Dr. Bryan became aware of the endocannabinoid system and began to attend cannabis industry conferences in order to gain more knowledge. In 2011 he established a relationship with the cannabinoid analysis company Cannatest and in 2012 began to represent Cannatest in the medical cannabis states of New England. In this role he educates legal caregivers and patients about the science of the endocannabinoid system, cannabis plant, and High Performance Thin Layer Chromatography cannabinoid analysis method. Dr. Bryan also works as a community pharmacist in Connecticut and is a member of the International Cannabinoid Research Society, Canadian Consortium for the investigation of Cannabinoids and the Society of Cannabis Clinicians.



Commenting on his appointment Dr. Bryan stated: "I am eager to lead the mCig Medical Advisory Board and contribute to the momentum of the company through the continued enhancement of vaporization efficiency. Additionally, I envision the mCig device as a delivery method for therapeutic plant secondary metabolite vapor and will be working toward this goal."



The company has previously stated that it is developing a new product codenamed: “VITA”. The company expects to update its shareholders on the progress of this new division in the coming weeks. This product will provide entry into a totally new market for mCig, Inc.



Non-Dilutive Transaction

As part of this appointment, Mr. Paul Rosenberg mCig CEO has committed to cancel an equal amount of his shares against any shares issued to Dr. Khary Bryan.


About mCig, Inc.

mCig, Inc. (Stock Market Symbol: MCIG) is a technology company focused on two long-term secular trends sweeping the globe: (1) The decriminalization and legalization of marijuana for medicinal or recreational purposes (2) The adoption of electronic vaporizing cigarettes (commonly known as “eCigs”) by the world’s 1.2 Billion smokers. - See more at: http://www.mcig.org/


The company believes that a well regulated marijuana industry is emerging as more states follow the lead of Washington and Colorado in legalizing marijuana. A similar trend is developing within the eCig industry following the first acquisition of an electronic cigarette brand (Blucigs) by a traditional tobacco company Lorillard Inc. (NYSE: LO) for $135 million. Wells Fargo (NYSE: WFC) analyst Bonnie Herzog estimates that eCig sales may rise from $1 Billion in 2013 to $10 billion over the next three years.

mCig, Inc. (Stock Market Symbol: MCIG) has positioned itself as a first mover at the intersection of these two trends and hopes to create shareholder value by making the mCig one of the leading choices for electronic consumption of plant material. - See more at: http://www.mcig.org/investors/

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.